PT  - JOURNAL ARTICLE
AU  - Murakami, Keita
AU  - Arai, Junya
AU  - Ihara, Sozaburo
AU  - Hirata, Yoshihiro
AU  - Tsuchida, Yumi
AU  - Shoda, Hirofumi
AU  - Tsuboi, Mayo
AU  - Kurokawa, Ken
AU  - Suzuki, Nobumi
AU  - Kinoshita, Hiroto
AU  - Hayakawa, Yoku
AU  - Fujio, Keishi
AU  - Fujishiro, Mitsuhiro
TI  - Association Between Proton Pump Inhibitors and the Risk of Intestinal Behçet Disease
AID  - 10.3899/jrheum.2024-0442
DP  - 2024 Dec 01
TA  - The Journal of Rheumatology
PG  - 1193--1197
VI  - 51
IP  - 12
4099  - http://www.jrheum.org/content/51/12/1193.short
4100  - http://www.jrheum.org/content/51/12/1193.full
SO  - J Rheumatol2024 Dec 01; 51
AB  - Objective This study aimed to investigate the association between proton pump inhibitor (PPI) use and the incidence of intestinal Behçet disease (BD) in patients with BD.Methods A retrospective cohort study was conducted at The University of Tokyo Hospital, including patients with BD diagnosed between April 2005 and November 2023. Cox models and Kaplan-Meier analyses were used to evaluate hazard ratios (HRs) and cumulative incidence of intestinal BD, respectively. Secondary analyses were performed to assess the duration and dose-response relationship of PPI use.Results Among 194 patients with BD, 25.3% developed intestinal BD during a mean follow-up of 12 years. PPI users had a significantly higher incidence of intestinal BD compared to nonusers (adjusted HR 2.48, 95% CI 1.38-4.47, P = 0.002), with a confirmed duration/dose-dependent relationship. The cumulative incidence of intestinal BD was markedly elevated in PPI users (log-rank P < 0.001). The result was similar to that in the propensity score–matched cohort.Conclusion This study demonstrates a significant association between PPI use and increased incidence of intestinal BD in patients with BD. Caution in prescribing PPIs for patients with BD is warranted due to the potential risk of severe complications associated with intestinal BD.